300009 Anhui Anke Biotechnology
- 9.23
- +0.11+1.21%
About Anhui Anke Biotechnology Company
The company is a high-tech enterprise whose main business is biomedical R&D, production, sales and service, and was one of the first companies listed on the China GEM. Adhering to the corporate mission of “technology interprets life, love achieves health”, it focuses on the main biomedical industry and cutting-edge technology development, and is committed to becoming a world-class provider of health products and health services. The company's parent company is committed to the R&D, production and sales of genetically-engineered drugs and biological detection reagents. The subsidiary's business covers R&D, production and sales of modern proprietary Chinese medicines, chemically synthesized drugs, peptide drugs, forensic DNA testing, cellular drugs, etc. The company's main products currently include biological products, products of the parent company and products of the subsidiary Anke Huajie, modern proprietary Chinese medicines, products of the subsidiary Yu Liangqing Company, chemically synthesized drugs, products of the subsidiary Anke Hengyi Company, peptide drugs, and products of the subsidiary Soho Yiming. Corporate honors include the third prize of the National Science and Technology Progress Award, the first prize of the Anhui Science and Technology Progress Award, and the second prize of the Anhui Science and Technology Progress Award. It won the “2019 National Technological Innovation Demonstration Enterprise”, the “Outstanding Contribution Award - High Growth and Quality Award”, “2018 High-tech Zone Advanced Production Safety Unit”, “Quality Improvement and Efficiency Award - Production Safety Award”, “Innovation and Entrepreneurship Award - Harmonious Labor Relations Demonstration Enterprise Award”, “Technology Finance Award - Innovative Financing Award”, “Advanced Statistics Award”, and “2019 Hefei Gaoling New Enterprise Award””, 2022 The “Love Contribution Award” of the China Children and Adolescents Charitable Relief Foundation, the 25th Golden Bull Award for Listed Companies - “2022 Golden Letter Award”, 2024 Future Health Industry Star Listed Company Honors, etc.
Company Profile
Company Executives
- Name
- Position
- Salary
- lihua song
- Chairman, Directors, President, Chairman of the Strategy and Investment Committee
- 2.71M
- yuanyuan zhou
- Vice Chairman, Directors, Audit Committee Member
- 635.00K
- liming song
- Vice Chairman, Directors
- 976.00K
- kun li
- Directors, Board Secretary, Director of Capital Operations
- 469.00K
- xianyu du
- Directors, Member of the Strategy and Investment Committee
- 503.00K
- junpei jiang
- Directors
- 501.50K
- yongbin wang
- Directors
- 501.00K
- hui zhao
- Directors, Senior Vice President, Member of the Remuneration and Assessment Committee
- 651.00K
- guangfu liu
- Independent Directors, Chairman of the Remuneration and Assessment Committee, Audit Committee Member
- 75.00K
- weidong zhu
- Independent Directors, Chairman of the Audit Committee
- 75.00K
- xiaoping geng
- Independent Directors, Member of the Remuneration and Assessment Committee
- 75.00K
- feihu chen
- Independent Directors, Member of the Strategy and Investment Committee
- 75.00K
- wenhui liu
- Securities Affairs Representative
- --
- zengli li
- Chairman of the Supervisory Board, Auditors
- 471.00K
- TA WEI CHOU
- VP
- 887.00K
- hongyi yao
- VP
- 531.00K
- hai sheng
- Senior Vice President
- 1.11M
- yinghui dou
- VP
- 687.00K
- chunyan lu
- VP
- 506.00K
- xueke bao
- VP
- 1.10M
- chenghao hu
- Chief Financial Officer
- 438.70K
- liefeng feng
- Head of Audit Department
- --
- jianping yao
- Executive President
- 857.00K
- chenghua li
- Employee Supervisors
- 315.00K
- yong wang
- Employee Supervisors
- 223.00K
Analysis
Price Target
No Data
No Data